TY  - JOUR
AU  - Cabezas Camarero, Santiago
AU  - Merino Menéndez, Salome
AU  - Cabrera Martín, María Nieves
AU  - Sotelo, Miguel J.
AU  - Plaza Hernández, José Carlos
AU  - Falahat Noushzady, Farzin
AU  - Iglesias Moreno, María Cruz
AU  - Pérez Segura, Pedro
PY  - 2023
DO  - 10.3892/ol.2022.13623
SN  - 1792-1074
UR  - https://hdl.handle.net/20.500.14352/131413
T2  - Oncology Letters
AB  - Novel chemo‑immunotherapy (chemo‑IO) combinations should be evaluated, which may be suitable for cisplatin‑unfit or fluoropyrimide‑ineligible patients with recurrent or metastatic squamous cell carcinoma of head and neck (R/M SCCHN) to guarantee...
LA  - eng
M2  - 37
PB  - Spandidos Publication
KW  - pembrolizumab
KW  - paclitaxel
KW  - chemoimmunotherapy
KW  - carboplatin
KW  - chemoimmunotherapy
KW  - carboplatin
TI  - Safety and efficacy of pembrolizumab-carboplatin-paclitaxel in cisplatin-unfit and/or fluoropyrimidine-ineligilible patients with pdl1- positive recurrent/metastatic head and neck cancer.
TY  - journal article
VL  - 25
ER  -